Advertisement
Table 1 Baseline characteristics of study participants
| Item | SCIT | Control | p-value |
|---|---|---|---|
| Baseline characteristics including outliers (all randomizedpatients) | |||
| n | 33 | 32 | |
| Female proportion [n (%)] | 11 (33.3%) | 10 (31.2%) | 0.534 |
| Mean age in years [mean (SD)] | 10.0 (3.1) | 10.6 (2.9) | 0.403 |
| GINA level 2 [n (%)] | 26 (78.8%) | 26 (81.2%) | 0.525 |
| GINA level 3 [n (%)] | 7 (21.2%) | 6 (18.8%) | |
| Mean peak flow in l/min [mean (SD)] | 296 (101) | 315 (91) | 0.444 |
| Mean annual costs for allergic-drugs before intervention onset in euro[mean (SD)] | 434 (332) | 296 (220) | 0.130 |
| Mean annual costs for non-allergic-drugs before intervention onset ineuro [mean (SD)] | 51 (87) | 50 (98) | 0.571 |
| Mean total annual drug costs before intervention onset in euro [mean(SD)] | 485 (377) | 345 (245) | 0.083 |
| Baseline characteristics without outliers (all analysedpatients) | |||
| n | 28 | 31 | |
| Female proportion [n (%)] | 8 (28.6%) | 10 (32.3%) | 0.785 |
| Mean age in years [mean (SD)] | 10.4 (3.2) | 10.8 (2.8) | 0.628 |
| GINA level 2 [n (%)] | 21 (75.0%) | 25 (80.6%) | 0.417 |
| GINA level 3 [n (%)] | 7 (25.0%) | 6 (19.4%) | |
| Mean asthma level GINA [mean (SD)] | 2.25 (0.441) | 2.19 (0.402) | 0.755 |
| Mean peak flow in l/min [mean (SD)] | 308 (105) | 317 (91) | 0.727 |
| Mean annual costs for allergic-drugs before intervention onset in euro[mean (SD)] | 315 (180) | 273 (183) | 0.443 |
| Mean annual costs for non-allergic-drugs before intervention onset ineuro [mean (SD)] | 33 (54) | 48 (99) | 0.974 |
| Mean total annual drug costs before intervention onset in euro [mean(SD)] | 349 (192) | 322 (209) | 0.627 |
